These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21442382)

  • 1. Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.
    Duntas LH; Stathatos N
    Endocrine; 2011 Jun; 39(3):199-204. PubMed ID: 21442382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the use of cinacalcet in the management of primary hyperparathyroidism.
    Marcocci C; Cetani F
    J Endocrinol Invest; 2012 Jan; 35(1):90-5. PubMed ID: 22104762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet for the treatment of primary hyperparathyroidism.
    Dillon ML; Frazee LA
    Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
    Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
    Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Medical treatment of primary hyperparathyroidism: role of calcimimetics].
    Muñoz Torres M; García Martín A
    Endocrinol Nutr; 2009 Apr; 56 Suppl 1():29-34. PubMed ID: 19627758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
    Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
    Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.
    Cetani F; Saponaro F; Banti C; Cianferotti L; Vignali E; Chiavistelli S; Viccica G; Pinchera A; Marcocci C
    J Endocrinol Invest; 2012 Jul; 35(7):655-60. PubMed ID: 21971564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.
    Marcocci C; Chanson P; Shoback D; Bilezikian J; Fernandez-Cruz L; Orgiazzi J; Henzen C; Cheng S; Sterling LR; Lu J; Peacock M
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2766-72. PubMed ID: 19470620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
    Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
    de Francisco AL
    Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utilization of cinacalcet in hypercalcemic conditions.
    Messa P; Alfieri C; Brezzi B
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):517-28. PubMed ID: 21361849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
    Khan A; Grey A; Shoback D
    J Clin Endocrinol Metab; 2009 Feb; 94(2):373-81. PubMed ID: 19193912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function.
    Nguyen S; Gosmanova EO; Gosmanov AR
    J Investig Med High Impact Case Rep; 2020; 8():2324709620936836. PubMed ID: 32583691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical management of primary hyperparathyroidism.
    Khan AA
    J Clin Densitom; 2013; 16(1):60-3. PubMed ID: 23374743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
    Imanishi Y; Kawata T; Kenko T; Wada M; Nagano N; Miki T; Arnold A; Inaba M
    Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical management of primary hyperparathyroidism with concomitant multiple myeloma.
    Fanari Z; Kadikoy H; Haque W; Pacha O; Abdellatif A
    Intern Med; 2010; 49(6):581-4. PubMed ID: 20228595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
    Akinci B; Comlekci A; Tankurt E
    Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):142-5. PubMed ID: 18561096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
    Norman J; Lopez J; Politz D
    Ann Surg Oncol; 2012 May; 19(5):1466-71. PubMed ID: 21922336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.